In patients with membranous nephropathy, alkylating agents (cyclophosphamide or
chlorambucil) alone or in combination with steroids achieve remission of nephrotic …

Membranous nephropathy is the most common cause of primary nephrotic syndrome among
adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in a …

Rituximab induces nephrotic syndrome (NS) remission in two-thirds of patients with primary
membranous nephropathy (MN), even after other treatments have failed. To assess the …

Background Membranous nephropathy leads to end-stage renal disease in more than 20%
of patients. Although immunosuppressive therapy benefits some patients, trial evidence for …

Primary membranous nephropathy (MN) is a kidney-specific autoimmune glomerular
disease and the leading cause of nephrotic syndrome (NS) in White adults, usually caused …

Membranous nephropathy (MN) is one of the most common causes of non-diabetic
nephrotic syndrome in adults. About 80% of cases are renal limited (primary MN) and 20 …

When first introduced, rituximab (RTX), a chimeric anti-CD20 monoclonal antibody, brought
about an alternative therapeutic paradigm for primary membranous nephropathy (PMN) …

Rituximab offers an alternative to current immunosuppressive therapies for difficult-to-treat
nephrotic syndrome. The best outcomes are seen in patients with steroid-dependent …

Background Idiopathic membranous nephropathy (MN) is a common immune-mediated
glomerular disease and the main cause of nephrotic syndrome (NS) in Caucasian adults …

Exciting progress recently has been made in our understanding of idiopathic membranous
nephropathy, as well as treatment of this disease. Here, we review important advances …